Clik here to view.
REVLIMID(R) Granted Swissmedic Approval for Treatment of Rare Blood Cancer
REVLIMID(R) Granted Swissmedic Approval for Treatment of Rare Blood Cancer BOUDRY, Switzerland–(BUSINESS WIRE)–Nov. 21, 2011– Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ:...
View ArticleClik here to view.
Dosing Study Evaluates REVLIMID® in Previously Treated Patients with Chronic...
Study Reported Overall Response Rate of 38%, and REVLIMID® (Lenalidomide) Was Well Tolerated BOUDRY, Switzerland–(BUSINESS WIRE)–Dec. 11, 2011– Celgene International Sàrl, a subsidiary of Celgene...
View ArticleClik here to view.
Final Data from Phase II Multi-Center Study Evaluating Combination of...
Patients achieving complete response had a median overall survival of 27 months BOUDRY, Switzerland, Dec 12, 2011 (BUSINESS WIRE) –Celgene International Sàrl, a subsidiary of Celgene Corporation...
View ArticleClik here to view.
BioNJ Presents Fifth Annual Dr. Sol J. Barer Award for Vision, Innovation,...
TRENTON, N.J.–(BUSINESS WIRE)–BioNJ, New Jersey’s trade association for the biotechnology community, announced today that the fifth annual Dr. Sol J. Barer Award for Vision, Innovation, and Leadership...
View ArticleClik here to view.
Celgene Corporation Announces the Appointment of Richard Bagger as Senior...
SUMMIT, N.J.–(BUSINESS WIRE)–Dec. 22, 2011– Celgene Corporation (NASDAQ: CELG) today announced the appointment of Richard Bagger as Senior Vice President, Corporate Affairs and Strategic Market Access,...
View ArticleClik here to view.
CELGENE CORPORATION ELECTS DR. RICHARD W. BARKER TO ITS BOARD OF DIRECTORS
Celgene Corporation (NASDAQ: CELG) today announced the election of Richard W. Barker, D.Phil., to its Board of Directors. Dr. Barker is a global thought leader in healthcare systems and government...
View ArticleClik here to view.
Celgene to Acquire Avila Therapeutics
Oral Btk inhibitor AVL-292 offers promising potential for treatment of B-cell diseases Avilomics™ Platform enhances drug discovery capabilities SUMMIT, N.J. and BEDFORD, Mass.–(BUSINESS WIRE)–Jan. 26,...
View ArticleClik here to view.
Celgene Corporation to Present at Two Upcoming Investor Conferences
SUMMIT, N.J.–(BUSINESS WIRE)–Feb. 27, 2012– Celgene Corporation (NASDAQ: CELG) announced its presentations at two upcoming investor conferences will be webcast live and will be available in the...
View ArticleClik here to view.
Celgene Completes Acquisition of Avila Therapeutics
SUMMIT, N.J.–(BUSINESS WIRE)–Mar. 8, 2012– Celgene Corporation (NASDAQ: CELG) today announced it has completed its acquisition of Avila Therapeutics. Celgene acquired Avila Therapeutics for $350...
View ArticleClik here to view.
Celgene Advances ABRAXANE® (nab-paclitaxel) Development in Difficult-to-Treat...
Phase III randomized clinical study in metastatic pancreatic cancer completed enrollment sNDA submitted to U.S. FDA in non-small cell lung cancer, PDUFA date Oct. 12, 2012 CALGB 40502 advances...
View Article
